<DOC>
	<DOCNO>NCT02371408</DOCNO>
	<brief_summary>The study assess efficacy PPI-668 ( USAN : ravidasvir hydrochloride ) combination sofosbuvir , without ribavirin , follow Egyptian HCV gt-4 patient population : 1 . Treatment-naïve patient , without cirrhosis ( Group 1 ) 2 . Previous non-responders interferon-based therapy , without cirrhosis ( Group 2 ) 3 . Previous non-responders interferon-based therapy , cirrhosis ( Group 3 )</brief_summary>
	<brief_title>A Study Efficacy Safety PPI-668 ( NS5A Inhibitor ) Plus Sofosbuvir , With Without Ribavirin , Patients With Chronic Hepatitis C Genotype-4</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>1 . Males female , ≥ 18 year &amp; ≤ 65 year age . 2 . HCV antibody positive , serum HCV RNA ≥ 10,000 IU/mL , clinical history compatible chronic hepatitis C. 3 . HCV genotype4 infection , confirm central study laboratory 4 . Body mass index ( BMI ) 18 35 kg/m2 , inclusive . 5 . Both male female patient childbearing potential must agree practice acceptable method birth control study least 6 month cessation treatment ; contraceptive method must include least one barrier method . 6 . Patients Group 1 must treatmentnaïve i.e. , never receive antiviral treatment HCV infection , include interferon , pegylated interferon , ribavirin , regulatoryapproved investigational HCV antiviral therapy . 7 . Patients Groups 2 3 must previously fail treatment interferonbased therapy i.e. , interferon pegylated interferon , without ribavirin , previous HCV antiviral therapy . Patients Group 2 must noncirrhotic diagnosed screen visit Fibroscan™ liver stiffness measurement &lt; 12.5 kPa FIB4 score &lt; 3.25 result Fibroscan FIB4 score matching ; liver biopsy use detection cirrhosis . In case liver biopsy applicable , hepatic image ultrasound report could use determination cirrhosis . Patients Group 3 must underlie cirrhosis diagnose screen visit Fibroscan liver stiffness measurement &gt; 12.5 kPa FIB4 score &gt; 3.25 , result Fibroscan FIB4 score match liver biopsy use detection cirrhosis . In case liver biopsy applicable , hepatic image ultrasound report could use determination cirrhosis . 8 . Willing able give inform consent 9 . Willing able complete study visit procedure , include compliance requirement restriction list consent form . 1 . Mixed genotype nontypable HCV genotype infection , 2 . Positive test HBsAg HIV antibody , IgM antibody HAV HEV 3 . History schistosomiasis positive test schistosoma surface antigen Screen . 4 . Serum alphafetoprotein ( AFP ) &gt; 100ng/ml . Patients AFP 50 100ng/ml may include long liver ultrasound within 3 month Screening , Screening , show evidence potential hepatocellular cancer . 5 . History treatment investigational regulatoryapproved directacting antiviral ( DAA ) agent HCV infection nucleos ( ) ide nonnucleosidic HCV polymerase inhibitor , HCV protease inhibitor , NS5A inhibitor , antiviral agent HCV infection pegylated interferon and/or ribavirin Previous pegylated interferon and/or ribavirin treatment allow Groups 2 3 prohibit group 1 , note Inclusion criterion 6 ) 6 . Evidence medical condition HCV contribute liver disease 7 . History , clinical sign , hepatic decompensation portal hypertension : Variceal bleeding , document esophageal GI varix ( investigator discretion , patient suspect esophageal varix evaluate endoscopy , varix exclude ) Ascites history physical examination Documented suspect hepatic encephalopathy Physical sign portal hypertension : Clinically significant splenomegaly Spider angiomata History portosystemic shunt procedure ( ) 8 . Uncontrolled diabetes mellitus evidence HgbA1C ≥ 8.5 % Screening . 9 . Hemoglobin &lt; 11g/dL female &lt; 12 g/dL male 10 . WBC count &lt; 3,500/mm3 OR absolute neutrophil count ( ANC ) &lt; 1800/mm 11 . Platelet count &lt; 75,000/mm3 12 . Serum creatinine &gt; 1.3 x ULN OR creatinine clearance ( GFR ) &lt; 50 mL/minute 13 . Serum ALT AST &gt; 10x ULN 14 . Serum albumin ≤ 3.2 g/dl 15 . Direct serum bilirubin &gt; 2xULN 16 . INR &gt; 1.7 . 17 . History poorly control asthma , one hospitalization emergency room visit previous 6 month 18 . History malignancy within last 5 year ( except prostate cancer still within Glisson 's capsule basal cell carcinoma skin ) . 19 . History alcohol abuse assess investigator within past 2 year , alcohol use pattern may interfere patient 's study compliance . Patients must abstain alcohol least 6 month prior study start . 20 . History drug abuse assess investigator within last 2 year . 21 . Pregnancy , include current lactation female patient , male patient partner pregnant , female patient intend become pregnant . 22 . Major surgery require overnight hospitalization within 3 month prior Screening 23 . Participation another clinical trial investigational drug device within 6 month prior Screening 24 . Current use history use within precede 6 month immunosuppressive immunemodulating agent , include : azathioprine , systemic corticosteroid ( prednisone prednisone equivalent 10mg/day 10 day ) , immunosuppressive agent . Use inhale steroid mild/moderate asthma topical steroid minor skin condition allow . 25 . History solid organ bone marrow transplantation . 26 . History use medication associate QT prolongation concurrently within 30 day prior Screening Visit , include : macrolides , antiarrhythmic agent , azoles , fluoroquinolones , tricyclic antidepressant . 27. correction , personal family history Torsades de Pointe . 28 . Cardiac ischemia history recurrent angina , clinically symptomatic cardiac abnormality , requirement cardiac pacemaker 29 . History know allergy ribavirin ( RBV ) , excipient investigational product , history drug allergy , opinion investigator , mitigates study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>